Literature DB >> 25881537

Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis.

Dharmendra Kumar1, Tuhina Banerjee, Chandra Bhan Pratap, Ragini Tilak.   

Abstract

Since the emergence of pathogenic non-albicans Candida species, a number of new isolates have been added to the list. One such unusual species is Candida auris (C. auris), recently isolated and studied in few reports. In this study, a case of vulvovaginitis caused by Candida auris incidentally identified by molecular methods using internal transcribed spacer polymerase chain reaction (ITS PCR) is described. Antifungal susceptibility testing revealed the isolate to be resistant to itraconazole (MIC ≥ 2 µg/ml) and expressed important virulence factors including phospholipase, proteinase and hemolysin activity. The patient was successfully treated with oral fluconazole and did not have any invasive fungemia. Very few cases of this emerging pathogen have been reported. However, its isolation from clinical specimens reveals the significance of non-albicans candida species over C. albicans and the diversity of Candida spp causing infections.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25881537     DOI: 10.3855/jidc.4582

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  24 in total

Review 1.  Candida auris: a Review of the Literature.

Authors:  Anna Jeffery-Smith; Surabhi K Taori; Silke Schelenz; Katie Jeffery; Elizabeth M Johnson; Andrew Borman; Rohini Manuel; Colin S Brown
Journal:  Clin Microbiol Rev       Date:  2017-11-15       Impact factor: 26.132

Review 2.  Candida auris: a fungus with identity crisis.

Authors:  Taissa Vila; Ahmed S Sultan; Daniel Montelongo-Jauregui; Mary Ann Jabra-Rizk
Journal:  Pathog Dis       Date:  2020-06-01       Impact factor: 3.166

3.  Candida auris Isolates of the Southern Asian and South African Lineages Exhibit Different Phenotypic and Antifungal Susceptibility Profiles In Vitro.

Authors:  Adrien Szekely; Andrew M Borman; Elizabeth M Johnson
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

Review 4.  Candida auris: an Emerging Fungal Pathogen.

Authors:  Emily S Spivak; Kimberly E Hanson
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

5.  Comparative Analysis of the Capacity of the Candida Species To Elicit Vaginal Immunopathology.

Authors:  Hubertine M E Willems; David J Lowes; Katherine S Barker; Glen E Palmer; Brian M Peters
Journal:  Infect Immun       Date:  2018-11-20       Impact factor: 3.441

6.  Development and Validation of a Real-Time PCR Assay for Rapid Detection of Candida auris from Surveillance Samples.

Authors:  L Leach; Y Zhu; S Chaturvedi
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

7.  The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.

Authors:  Emily Larkin; Christopher Hager; Jyotsna Chandra; Pranab K Mukherjee; Mauricio Retuerto; Iman Salem; Lisa Long; Nancy Isham; Laura Kovanda; Katyna Borroto-Esoda; Steve Wring; David Angulo; Mahmoud Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

8.  Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris.

Authors:  Leighann Sherry; Gordon Ramage; Ryan Kean; Andrew Borman; Elizabeth M Johnson; Malcolm D Richardson; Riina Rautemaa-Richardson
Journal:  Emerg Infect Dis       Date:  2017-02       Impact factor: 6.883

Review 9.  Candida auris: From Multidrug Resistance to Pan-Resistant Strains.

Authors:  Muluneh Ademe; Friehiwot Girma
Journal:  Infect Drug Resist       Date:  2020-05-05       Impact factor: 4.003

10.  Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida Species.

Authors:  Andrew M Borman; Adrien Szekely; Elizabeth M Johnson
Journal:  mSphere       Date:  2016-08-18       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.